WebClinphenomics. Study for Diploma in Biology at Göttingen University. Dieses Profil melden Melden Melden. Zurück Senden. Info I am biologist (Dr. rer. nat.) with experience in the scientific and clinical research. After a family break as a mother of three children, I have completed a one-year training on the journals editor in 2000. WebOur Technology. Phinomics bridges engineering disciplines with immunology and cancer biology to prevent, diagnose, and treat disorders driven by changes in DNA. We provide …
Finerenone (Kerendia, BAY94-8862 ) and Empagliflozin on Type 2 …
WebThe primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease. After completion of the interventional part of the study (primary study completion) a subset of participants will be followed up in a post-trial … WebFeb 4, 2024 · Inclusion Criteria: Participant with a clinical diagnosis of chronic kidney disease (CKD) and the following: In Part A: eGFR 40-90 ml/min/1.73m^2 (with no more than 20% having an eGFR >75 ml/min/1.73m^2) using Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula at screening visit and at least one historical value of … navus medication
Business Directory - Dun & Bradstreet
WebClinPhenomics GmbH&Co KG, study center Frankfurt. Okt. 2004–Heute18 Jahre 6 Monate. Frankfurt, Germany. Clinical research, focus on cardiovascular and metabolic studies, primarily phase II and III, especially clinical outcome studies. WebAug 19, 2024 · A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in … WebJul 18, 2024 · The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in … navusoft reviews